yttrium Y 90-ibritumomab tiuxetan (IH-tree-um ... ih-brih-TOO-moh-mab ty-UK-seh-tan)
A drug used with the drug rituximab to treat certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the treatment of other types of B-cell tumors. Yttrium Y 90-ibritumomab tiuxetan contains a monoclonal antibody that binds to a protein called CD20, which is found on B cells. It also contains a radioactive substance called yttrium Y 90, which may help kill cancer cells. Yttrium Y 90-ibritumomab tiuxetan is a type of radioimmunoconjugate. Also called 90Y-ibritumomab tiuxetan, 90Y-Zevalin, and IDEC-Y2B8.